Diloxanide API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Diloxanide is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Diloxanide or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Diloxanide API 579-38-4?

Description:
Here you will find a list of producers, manufacturers and distributors of Diloxanide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Diloxanide 
Cas Number:
579-38-4 
DrugBank number:
DB08792 
Unique Ingredient Identifier:
89134SCM7M

About Diloxanide

Why are people looking for Diloxanide? Diloxanide (as Diloxanide furoate) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 471 cases of Entamoeba histolytica from 1977 to 1990.

You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.

Diloxanide is a type of Antiprotozoics


Antiprotozoics are a vital subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) used to combat protozoan infections. Protozoa are single-celled microorganisms that can cause severe diseases in humans, such as malaria, leishmaniasis, and toxoplasmosis. Antiprotozoic APIs play a crucial role in the development of effective medications to treat these infections.

These APIs work by targeting specific metabolic pathways or enzymes within the protozoan organisms, effectively inhibiting their growth and reproduction. By interrupting essential processes, antiprotozoics can eliminate the protozoa from the body or suppress their activity, allowing the immune system to effectively combat the infection.

Pharmaceutical companies invest significant efforts in research and development to discover and synthesize new antiprotozoic APIs. The goal is to develop highly potent and selective compounds that can effectively eradicate protozoa while minimizing side effects on the human body. This involves rigorous testing and screening of various chemical compounds to identify potential drug candidates with optimal therapeutic properties.

Antiprotozoic APIs are then used as the active ingredients in the formulation of pharmaceutical drugs, such as tablets, capsules, or injectables. These drugs are prescribed by healthcare professionals to patients suffering from protozoan infections. The selection of the appropriate antiprotozoic API depends on the specific protozoan strain and the characteristics of the infection.

In summary, antiprotozoic APIs are essential pharmaceutical ingredients that play a vital role in treating protozoan infections. Their development involves rigorous research and testing to identify potent compounds that can effectively target and eliminate protozoa, leading to improved health outcomes for patients.


Diloxanide (Antiprotozoics), classified under Antiparasitics


Antiparasitics are a category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that are used to combat parasitic infections in humans and animals. These APIs play a crucial role in the field of medicine and veterinary care by targeting and eliminating various parasites, such as protozoa, helminths, and ectoparasites.

The use of antiparasitics is essential in preventing and treating parasitic diseases, which can cause significant health issues and even be life-threatening. These APIs work by interfering with the parasite's vital biological processes, such as reproduction, metabolism, and survival mechanisms.

Pharmaceutical companies develop and manufacture a wide range of antiparasitic APIs to cater to different parasitic infections. Some common examples of antiparasitics include anthelmintics (used against intestinal worms), antimalarials (used to treat malaria), and ectoparasiticides (used to control external parasites like ticks and fleas).

The development of antiparasitic APIs requires rigorous research, including the identification of suitable targets within the parasite's biology and the formulation of effective chemical compounds. Safety and efficacy are paramount in the manufacturing of antiparasitics, ensuring that they effectively combat the targeted parasites while minimizing adverse effects on the host.

Overall, antiparasitics are vital tools in the fight against parasitic infections, benefiting both human and animal health. Through ongoing research and development, the pharmaceutical industry continues to innovate and improve antiparasitic APIs, contributing to the advancement of healthcare and the well-being of individuals and their animal companions.